Lützen U - Search Results

1

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. Rahbar K, et al. Among authors: lutzen u. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20. J Nucl Med. 2017. PMID: 27765862 Free article.

2

Value and Efficacy of Sentinel Lymph Node Diagnostics in Patients With Penile Carcinoma With Nonpalpable Inguinal Lymph Nodes: Five-Year Follow-up.

Lützen U, Zuhayra M, Marx M, Zhao Y, Knüpfer S, Colberg C, Jünemann KP, Naumann CM. Lützen U, et al. Clin Nucl Med. 2016 Aug;41(8):621-5. doi: 10.1097/RLU.0000000000001268. Clin Nucl Med. 2016. PMID: 27276200

3

[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].

Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. Fendler WP, et al. Among authors: lutzen u. Nuklearmedizin. 2016 Jun 28;55(3):123-8. Nuklearmedizin. 2016. PMID: 27350005 German.

4

10-Year experience regarding the reliability and morbidity of radio guided lymph node biopsy in penile cancer patients and the associated radiation exposure of medical staff in this procedure.

Lützen U, Naumann CM, Dischinger J, Marx M, Baumann R, Zhao Y, Jüptner M, Osmonov D, Bothe K, Jünemann KP, Zuhayra M. Lützen U, et al. BMC Urol. 2016 Aug 2;16(1):47. doi: 10.1186/s12894-016-0166-2. BMC Urol. 2016. PMID: 27485215 Free PMC article.

5

Value and efficiency of sentinel lymph node diagnostics in patients with penile carcinoma with palpable inguinal lymph nodes as a new multimodal, minimally invasive approach.

Lützen U, Zuhayra M, Marx M, Zhao Y, Colberg C, Knüpfer S, Baumann R, Kähler KC, Jünemann KP, Naumann CM. Lützen U, et al. Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2313-2323. doi: 10.1007/s00259-016-3482-6. Epub 2016 Aug 12. Eur J Nucl Med Mol Imaging. 2016. PMID: 27519598 Clinical Trial.

6

A study on the value of computer-assisted assessment for SPECT/CT-scans in sentinel lymph node diagnostics of penile cancer as well as clinical reliability and morbidity of this procedure.

Lützen U, Naumann CM, Marx M, Zhao Y, Jüptner M, Baumann R, Papp L, Zsótér N, Aksenov A, Jünemann KP, Zuhayra M. Lützen U, et al. Cancer Imaging. 2016 Sep 7;16(1):29. doi: 10.1186/s40644-016-0087-z. Cancer Imaging. 2016. PMID: 27604900 Free PMC article.

7

Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Lützen U, Zhao Y, Lucht K, Zuhayra M, Marx M, Cascorbi I, Culman J. Lützen U, et al. Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):37-48. doi: 10.1007/s00210-016-1291-x. Epub 2016 Sep 23. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 27664035

8

Evaluation of the diagnostic value of preoperative sentinel lymph node (SLN) imaging in penile carcinoma patients without palpable inguinal lymph nodes via single photon emission computed tomography/computed tomography (SPECT/CT) as compared to planar scintigraphy.

Naumann CM, Colberg C, Jüptner M, Marx M, Zhao Y, Jiang P, Hamann MF, Jünemann KP, Zuhayra M, Lützen U. Naumann CM, et al. Among authors: lutzen u. Urol Oncol. 2018 Mar;36(3):92.e17-92.e24. doi: 10.1016/j.urolonc.2017.11.012. Epub 2017 Dec 14. Urol Oncol. 2018. PMID: 29249274

9

Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma.

Jüptner M, Marx M, Zuhayra M, Lützen U. Jüptner M, et al. Among authors: lutzen u. Nuklearmedizin. 2019 Aug;58(4):328-330. doi: 10.1055/a-0914-2486. Epub 2019 May 28. Nuklearmedizin. 2019. PMID: 31140181

10

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.

Wrenger R, Jüptner M, Marx M, Zhao Y, Zuhayra M, Caliebe A, Osmonov D, Lützen U. Wrenger R, et al. Among authors: lutzen u. BMC Urol. 2022 Jul 4;22(1):96. doi: 10.1186/s12894-022-01050-3. BMC Urol. 2022. PMID: 35788220 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page